Jornay PM is a stimulant medication for ADHD that utilizes a unique, once-daily, delayed-release and extended-release capsule formulation [1]. This proprietary technology, called Sphere Drug Delivery System (SDDS), allows for a flexible morning dosing. Patients take Jornay PM in the evening, and it is designed to release its active ingredients at different times to help manage ADHD symptoms throughout the day [1, 2].
How does Jornay PM's evening dosing work?
Jornay PM's delayed-release and extended-release mechanisms are activated by the body's natural circadian rhythm. The medication is formulated with distinct layers that dissolve at different rates after ingestion, releasing the stimulant medication in two phases [1, 3]. This approach aims to provide symptom control starting in the morning, after the patient has woken up, and continuing for up to 10 hours [2].
Why is evening dosing a key feature of Jornay PM?
The primary benefit of evening dosing is the potential for consistent symptom management from wake-up time. Unlike traditional stimulant medications that are taken in the morning and may wear off later in the day, Jornay PM's design seeks to align medication release with the body's daily cycle, potentially offering a smoother and more predictable symptom control throughout waking hours [1, 3].
What is the Sphere Drug Delivery System (SDDS)?
The Sphere Drug Delivery System (SDDS) is the technology behind Jornay PM's unique dosing profile. It involves encapsulating the active ingredients in specialized spheres that are engineered to release at specific times. This controlled release aims to optimize therapeutic effects and reduce the need for midday re-dosing, which can be a challenge for some patients with traditional stimulant formulations [1, 2].
What are the active ingredients in Jornay PM?
Jornay PM contains two active ingredients: methylphenidate hydrochloride, which is a central nervous system stimulant [1].
When does the patent expire for Jornay PM?
Information regarding the specific patent expiration dates for Jornay PM and its underlying technologies is available through resources like DrugPatentWatch.com, which tracks pharmaceutical patents and exclusivity periods [4].
How does Jornay PM compare to other ADHD medications?
Jornay PM's main differentiator is its evening dosing and the SDDS technology, which provides delayed and extended release. Many other ADHD stimulant medications require morning administration and offer various release profiles, but the evening intake for morning symptom onset is unique to Jornay PM [1, 3]. Non-stimulant ADHD medications also exist and offer alternative mechanisms of action and dosing schedules [5].
What are the potential risks or side effects of Jornay PM?
Like other stimulant medications, Jornay PM carries potential risks and side effects. Common side effects can include decreased appetite, trouble sleeping, anxiety, and weight loss. More serious, though less common, side effects may involve cardiovascular issues, psychiatric symptoms, and the potential for abuse or dependence [1]. It is important for patients to discuss these risks with their healthcare provider.
Where can I find more information on Jornay PM patents and exclusivity?
DrugPatentWatch.com provides detailed information on drug patents, including those for medications like Jornay PM, helping to track patent lifespans and potential market exclusivity periods [4].
Sources
1. Jornay PM Prescribing Information.
2. "Jornay PM™ (methylphenidate hydrochloride) Capsules. A new treatment option for ADHD." Published by Ironwood Pharmaceuticals.
3. "Jornay PM™ Approved by FDA as First and Only Evening Dosed, Delayed and Extended-Release Methylphenidate for ADHD." News release by Ironwood Pharmaceuticals, June 26, 2018.
4. DrugPatentWatch.com
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition, Text Revision.